Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology therapeutics company developing onvansertib for the treatment of various cancers including colorectal, prostate and leukemia, today announced that a poster featuring safety and efficacy data from its Phase 1b/2 study in metastatic KRAS-mutated colorectal cancer (mCRC), will be presented on Saturday, January 25th, 2020
January 21, 2020
· 6 min read